Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex–pulmonary disease in patients unsuitable for standard treatment regimen

氯法齐明 文化转换 医学 养生 分枝杆菌复合群 痰培养 外科 肺结核 内科学 麻风病 免疫学 病理
作者
Shengjuan Bao,Suting Chen,Jifang Zheng,J. Ma,Jiali Yang,Hairong Huang,Hongfei Duan
出处
期刊:International Journal of Antimicrobial Agents [Elsevier BV]
卷期号:63 (2): 107061-107061 被引量:1
标识
DOI:10.1016/j.ijantimicag.2023.107061
摘要

: Patients with Mycobacterium avium complex-pulmonary disease (MAC-PD) can exhibit contraindications in applying the recommended treatment regimens by the guidelines. Clofazimine (CFZ) is considered a promising drug for MAC-PD treatment and is frequently included in alternative regimens; however, its efficacy remains unclear. : MAC-PD patients, unsuitable for standard regimens, were enrolled continuously in a prospective study at Beijing Chest Hospital. The treatment response of the CFZ-containing regimen was monitored. : Fifty patients were enrolled in the initial treatment, and 25 patients had a history of anti-TB treatment. Nodular bronchiectasis was observed in 34 patients, while 8 patients exhibited fibrocavitary changes. Additionally, 8 patients displayed a combination of both patterns. In a multivariate analysis, MAC-PD patients with CFZ MIC< 0.25 mg/L were significantly associated with culture conversion [OR 8.415, 95% CI (1.983-35.705); P =0.004]. Among patients who had previous TB treatment history, patients with CFZ MIC < 0.25 mg/L had a higher chance of acquiring culture conversion outcomes [(OR 7.737, 95% CI 1.032-57.989); P =0.046]. In contrast, among patients with no previous TB treatment history, the RIF-containing regimen had a higher chance of acquiring culture conversion outcomes [(OR 11.038, 95%CI 1.008-120.888); P = 0.049]. : MAC-PD patients unsuitable for standard regimens could benefit from a CFZ-containing regimen, especially for patients with previous TB treatment history and baseline CFZ MIC values lower than 0.25 mg/L.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
2秒前
2秒前
HuiJN完成签到 ,获得积分10
2秒前
锤子完成签到,获得积分10
3秒前
在水一方应助lizibelle采纳,获得10
4秒前
hoyden完成签到,获得积分10
4秒前
Stardust发布了新的文献求助10
5秒前
7秒前
momo发布了新的文献求助10
8秒前
8秒前
乐乐应助Mo采纳,获得10
9秒前
9秒前
Liufgui应助Z6kjoA采纳,获得20
9秒前
爆米花应助科研通管家采纳,获得10
11秒前
NexusExplorer应助科研通管家采纳,获得10
11秒前
cangy发布了新的文献求助10
11秒前
英姑应助科研通管家采纳,获得10
11秒前
地表飞猪应助科研通管家采纳,获得10
11秒前
桐桐应助科研通管家采纳,获得10
11秒前
12秒前
Akim应助科研通管家采纳,获得10
12秒前
Orange应助科研通管家采纳,获得10
12秒前
地表飞猪应助科研通管家采纳,获得10
12秒前
科研通AI2S应助科研通管家采纳,获得10
12秒前
酷波er应助科研通管家采纳,获得10
12秒前
地表飞猪应助科研通管家采纳,获得10
12秒前
12秒前
YamDaamCaa应助科研通管家采纳,获得30
12秒前
luo关闭了luo文献求助
13秒前
Jogging完成签到,获得积分10
14秒前
Villanellel发布了新的文献求助30
14秒前
李健应助ttt采纳,获得10
14秒前
科目三应助xueyu采纳,获得10
15秒前
Jello完成签到,获得积分10
18秒前
18秒前
111完成签到,获得积分10
19秒前
qq完成签到 ,获得积分10
19秒前
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173